Full instructions on how to purchase and install TGC 2019
1 post • Page 1 of 1
The latest trial of the vaccine against the HIV รีวิวเกมสล็อตvirus that causes AIDS. Has been temporarily discontinued because it was found to be ineffective enough.
The US National Institutes of Health (NIH), based in Maryland, announced Monday. It ended the study of the HVTN 702 vaccine in South Africa on the recommendation of an independent committee governing information and safety.
The Uhambo study used volunteers at risk of infection. Both female and male aged 18-35 years, there are 5,407 people in 14 areas across South Africa. Since the year. These volunteers will be randomized to vaccinate. Both are vaccines that are likely to produce results. And 6 dummy vaccines
During an 18-month period, which is sufficient time for the vaccine to stimulate an immune response in the body. The researchers found that among those who received the vaccine There were 129 people with HIV and in the placebo group. 123 people were infected with HIV, and this study found no significant evidence. Indicating that vaccination can reduce or increase the rate of infection
The South African trial is an extension of previous RV144 vaccine trials in Thailand. RV144 is the only vaccine that has ever been successful in protecting against various levels of the HIV virus. The scientists said they will continue to study the results of the HVTN 702 vaccine trial to see why the moderately effective vaccine in Thailand was not effective in South Africa.
However, the researchers said there were no concerns. About the safety of the said vaccine
Experts have expressed disappointment in the decision to end the vaccine trial in South Africa.
Linda-Gail Bekker, former president of the International AIDS Association and chairman of the Enterprise Advisory Group, said that although the trial had failed. But it is still necessary to continue the search for a vaccine against the HIV virus. And that the unpredictable rate of HIV infection in the region is Should stimulate more urgent international interest and investment in research studies
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, part of the NIH, said the HIV vaccine was crucial in ending the global epidemic. The institute expects the vaccine to be effective. Unfortunately, the trial failed.UNAIDS data indicated that South Africa had one of the highest rates of HIV infection in the world in 2018, with people between the ages of 15 and 49 infected with H. More than 20% of HIV and a wide variety of HIV vaccines have been tried since the 1950s. 1990